ChemoCentryx has received US FDA (Food and Drug Administration) approval for their drug, avacopan, to treat the rare, fatal autoimmune disease, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). The oral drug, brand name Tavneos, will help those with the rare disease, which is characterized by the damage and irritation of small blood vessels impacting different organs, particularly the kidney, by stopping the activity of C5a receptor. The rare disease affects approximately 40,000 people in the unites states.

Read more here.

More on: